Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04077463
Title A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)
Acronym Chrysalis-2
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.